CMV: Long-Awaited Trial of HPMPC

Mt. Zion Medical Center of the University of California San
Francisco is initiating the first human study of HPMPC, a
nucleotide analog which is more potent against CMV, in laboratory
tests, than ganciclovir or foscarnet. (AIDS TREATMENT NEWS first
reported on HPMPC as a potential treatment for CMV infection over
three years ago, in issue #76, March 24, 1989).

The Mt. Zion protocol is a phase I/II study which will
administer the drug intravenously once a week. It is open to
people who are culture-positive for CMV, but who have not been
treated before with ganciclovir or foscarnet, and who are not
showing symptoms of active infection. The work-up and monitoring
for this study are intensive, involving two overnight hospital
stays; participants will be reimbursed $400.

For more information, interested persons should call Eileen
Glutzer, RN, or Jay Lalezari, M. D., at 415/476-6356.